237 related articles for article (PubMed ID: 29644723)
1. A French observational study describing the use of human polyvalent immunoglobulins in hematological malignancy-associated secondary immunodeficiency.
Benbrahim O; Viallard JF; Choquet S; Royer B; Bauduer F; Decaux O; Crave JC; Fardini Y; Clerson P; Lévy V
Eur J Haematol; 2018 Jul; 101(1):48-56. PubMed ID: 29644723
[TBL] [Abstract][Full Text] [Related]
2. The use of octagam and gammanorm in immunodeficiency associated with hematological malignancies: a prospective study from 21 French hematology departments.
Benbrahim O; Viallard JF; Choquet S; Royer B; Bauduer F; Decaux O; Crave JC; Fardini Y; Clerson P; Lévy V
Hematology; 2019 Dec; 24(1):173-182. PubMed ID: 30458690
[TBL] [Abstract][Full Text] [Related]
3. Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies.
Na IK; Buckland M; Agostini C; Edgar JDM; Friman V; Michallet M; Sánchez-Ramón S; Scheibenbogen C; Quinti I
Eur J Haematol; 2019 Jun; 102(6):447-456. PubMed ID: 30801785
[TBL] [Abstract][Full Text] [Related]
4. A summertime pause in immunoglobulin replacement therapy: a prospective real-world analysis.
Hémar V; Rivière E; Greib C; Machelart I; Roucoules M; Prot C; Pellegrin JL; Viallard JF; Lazaro E
Immunotherapy; 2021 Dec; 13(18):1491-1499. PubMed ID: 34743547
[TBL] [Abstract][Full Text] [Related]
5. Utilization of intravenous or subcutaneous immunoglobulins in secondary immune deficiency (ULTIMATE): A retrospective multicenter study.
Legendre P; Chahwan D; Marjanovic Z; Vignon M; Hermine O; Lortholary O; Morelle G; Darrodes M; Kahn JE; Ouzegdouh M; Chaibi P; Montestruc F; Caumont-Prim A; Le Jouan M; Hassani Y; Godeau B; Durand-Zaleski I; Mouthon L
Clin Immunol; 2020 Jun; 215():108419. PubMed ID: 32289463
[TBL] [Abstract][Full Text] [Related]
6. Post-marketing observational study on 5% intravenous immunoglobulin therapy in patients with secondary immunodeficiency and recurrent serious bacterial infections.
Günther G; Dreger B
Microbiol Immunol; 2013 Jul; 57(7):527-35. PubMed ID: 23607863
[TBL] [Abstract][Full Text] [Related]
7. Reduced risk of infections with the intravenous immunoglobulin, IgPro10, in patients at risk of secondary immunodeficiency-related infections.
Lahue BJ; Mallick R; Zhang X; Heidt J; Song Y; Koenig AS; Espinoza G
Immunotherapy; 2022 Oct; 14(15):1245-1261. PubMed ID: 35971794
[TBL] [Abstract][Full Text] [Related]
8. A systematic literature review of the effects of immunoglobulin replacement therapy on the burden of secondary immunodeficiency diseases associated with hematological malignancies and stem cell transplants.
Monleón Bonet C; Waser N; Cheng K; Tzivelekis S; Edgar JDM; Sánchez-Ramón S
Expert Rev Clin Immunol; 2020 Sep; 16(9):911-921. PubMed ID: 32783541
[TBL] [Abstract][Full Text] [Related]
9. Infections in secondary immunodeficiency patients treated with Privigen
Mallick R; Divino V; Smith BD; Jolles S; DeKoven M; Vinh DC
Leuk Lymphoma; 2021 Dec; 62(14):3463-3473. PubMed ID: 34569910
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic immunoglobulin therapy in secondary immune deficiency - an expert opinion.
Agostini C; Blau IW; Kimby E; Plesner T
Expert Rev Clin Immunol; 2016 Sep; 12(9):921-6. PubMed ID: 27415820
[TBL] [Abstract][Full Text] [Related]
11. Discontinuation of immunoglobulin replacement therapy in patients with secondary antibody deficiency.
Patel V; Cowan J
Expert Rev Clin Immunol; 2020 Jul; 16(7):711-716. PubMed ID: 32588670
[TBL] [Abstract][Full Text] [Related]
12. Immunoglobulin substitution in patients with secondary antibody deficiency in chronic lymphocytic leukemia and multiple myeloma: a representative analysis of guideline adherence and infections.
Link H; Kerkmann M; Holtmann L; ;
Support Care Cancer; 2022 Jun; 30(6):5187-5200. PubMed ID: 35257229
[TBL] [Abstract][Full Text] [Related]
13. Controversies about immunoglobulin replacement therapy in HSCT recipients with hypogammaglobulinemia.
Ohmoto A; Fuji S; Shultes KC; Savani BN; Einsele H
Bone Marrow Transplant; 2022 Jun; 57(6):874-880. PubMed ID: 35440805
[TBL] [Abstract][Full Text] [Related]
14. Immunoglobulin replacement in hematological malignancies: a focus on evidence, alternatives, dosing strategy, and cessation rule.
Sim B; Ng JY; Teh BW; Talaulikar D
Leuk Lymphoma; 2023 Jan; 64(1):18-29. PubMed ID: 36218218
[TBL] [Abstract][Full Text] [Related]
15. Management of secondary immunodeficiency in hematological malignancies in the era of modern oncology.
Shah N; Mustafa SS; Vinh DC
Crit Rev Oncol Hematol; 2023 Jan; 181():103896. PubMed ID: 36528276
[TBL] [Abstract][Full Text] [Related]
16. Cancer Therapy-associated Lymphoproliferative Disorders: An Under-recognized Type of Immunodeficiency-associated Lymphoproliferative Disorder.
Pina-Oviedo S; Miranda RN; Medeiros LJ
Am J Surg Pathol; 2018 Jan; 42(1):116-129. PubMed ID: 29112013
[TBL] [Abstract][Full Text] [Related]
17. Efficacy-safety of Facilitated Subcutaneous Immunoglobulin in Immunodeficiency Due to Hematological Malignancies. A Single-Center Retrospective Analysis.
Dimou M; Iliakis T; Maltezas D; Bitsani A; Kalyva S; Koudouna A; Kotsanti S; Petsa P; Papaioannou P; Kyrtsonis MC; Panayiotidis P
Anticancer Res; 2018 Jul; 38(7):4187-4191. PubMed ID: 29970548
[TBL] [Abstract][Full Text] [Related]
18. Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation.
Kumar AJ; Hexner EO; Frey NV; Luger SM; Loren AW; Reshef R; Boyer J; Smith J; Stadtmauer EA; Levine BL; June CH; Porter DL; Goldstein SC
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1094-101. PubMed ID: 23635453
[TBL] [Abstract][Full Text] [Related]
19. Management of patients with malignancies and secondary immunodeficiencies treated with immunoglobulins in clinical practice: Long-term data of the SIGNS study.
Reiser M; Borte M; Huscher D; Baumann U; Pittrow D; Sommer C; Stangel M; Fasshauer M; Gold R; Hensel M
Eur J Haematol; 2017 Aug; 99(2):169-177. PubMed ID: 28467615
[TBL] [Abstract][Full Text] [Related]
20. Immunoglobulin use in immune deficiency in the UK: a report of the UKPID and National Immunoglobulin Databases.
Shillitoe B; Hollingsworth R; Foster M; Garcez T; Guzman D; Edgar JD; Buckland M
Clin Med (Lond); 2018 Oct; 18(5):364-370. PubMed ID: 30287427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
